OM
Opaleye Management Portfolio holdings
AUM
$494M
1-Year Return
68.17%
This Quarter Return
-20.34%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$268M
AUM Growth
-$125M
(-32%)
Cap. Flow
-$30.8M
Cap. Flow
% of AUM
-11.49%
Top 10 Holdings %
Top 10 Hldgs %
57.14%
Holding
61
New
14
Increased
11
Reduced
11
Closed
14
Top Buys
| 1 |
Avalo Therapeutics
AVTX
|
$6.21M |
| 2 |
EPZM
Epizyme, Inc
EPZM
|
$5.7M |
| 3 |
IMGN
Immunogen Inc
IMGN
|
$4.9M |
| 4 |
AIMT
Aimmune Therapeutics, Inc.
AIMT
|
$3.59M |
| 5 |
Abeona Therapeutics
ABEO
|
$3.21M |
Top Sells
| 1 |
Agios Pharmaceuticals
AGIO
|
$10M |
| 2 |
AMAG
AMAG Pharmaceuticals, Inc.
AMAG
|
$8.4M |
| 3 |
Xenon Pharmaceuticals
XENE
|
$7.01M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$6.11M |
| 5 |
Ocular Therapeutix
OCUL
|
$5.5M |
Sector Composition
| 1 | Healthcare | 98.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Iovance Biotherapeutics
IOVA
$771M
| – | – |
-325,000
| Closed | -$3.66M |
|
|
52
Ocular Therapeutix
OCUL
$2.22B
| – | – |
-800,000
| Closed | -$5.5M |
|
|
53
Ultragenyx Pharmaceutical
RARE
$3.03B
| – | – |
-80,000
| Closed | -$6.11M |
|
|
54
Xenon Pharmaceuticals
XENE
$2.96B
| – | – |
-465,200
| Closed | -$7.01M |
|
|
TVRD
55
Tvardi Therapeutics, Inc. Common Stock
TVRD
$277M
| – | – |
-3,611
| Closed | -$3.11M |
|
|
INFI
56
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| – | – |
-275,000
| Closed | -$745K |
|
|
BFRA
57
DELISTED
Biofrontera AG American Depositary Shares
BFRA
| – | – |
-79,007
| Closed | -$1.07M |
|
|
AMAG
58
DELISTED
AMAG Pharmaceuticals, Inc.
AMAG
| – | – |
-420,000
| Closed | -$8.4M |
|
|
FOMX
59
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| – | – |
-91,000
| Closed | -$521K |
|
|
ACHN
60
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| – | – |
-275,000
| Closed | -$1.01M |
|
|
CORI
61
DELISTED
Corium International, Inc.
CORI
| – | – |
-550,000
| Closed | -$5.23M |
|